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Abstract: In the recentmostmelioidosismeeting inManipal (1st
South Asian Melioidosis Congress) in November, 2015, Dr. David
Dance from University of Oxford told that ‘nearly 165,000 peo-
ple is getting affected with melioidosis every year in the world,
out of which 44% are from South Asian countries’, and further he
added that ‘Indiahas thehighest burden,withmore than50%death,
which are mostly undiagnosed’. It is predicted that Indian subcon-
tinent is presently the ‘hot spot’ of the disease, which has most
number of cases and deaths. After the bacterium was discovered
by the Indian bacteriologist, CS Krishnaswami, in 1912, along with
his physician colleague, A.Whitmore, it took almost 80years (1991)
to diagnose the ﬁrst case of melioidosis in an Indian medical set up
in Mumbai. Since then, only 50 cases have been published in last
25 years, which may merely be considered as the ‘tip of the ice-
berg’. During our last 10 years journey with melioidosis research,
we have performed the ﬁrst extensive seroprevalence study with
29% seropositivity rate, which proved beyond doubt the signiﬁcant
environmental exposure to B. pseudomallei in the soil and water.
Nearly 200 patients withmelioidosis were detected in last 10 years
in our tertiary care hospital predominantly with pneumonia and
highmortality andmostly during heavy rainfall. Our improved lab-
oratory set up help us diagnose cases rapidly and more accurately,
and serve as the reference center for melioidosis in this region.
Humans acquiremelioidosis following contactwith B. pseudomallei
in the environment. We have detected the presence of B. pseu-
domallei while performing soil surveillance in and around Udupi
district with nearly 40% positivity rate. Our clinical isolates are
found to be diverse from Australian and Southeast Asian strains,
suggesting their pure Indian origin more strongly. To strengthen
the melioidosis research in this subcontinent, Indian Melioidosis
Research Forum is formed with scientists and researchers from all
over the world, with a more focused case ﬁnding from eastern and
north-eastern states of India.
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Abstract: Burkholderia pseudomallei, a highly pathogenic bac-
terium that causes melioidosis, is commonly found in soil in
Southeast Asia and Northern Australia. Melioidosis can be difﬁ-
cult to diagnose due to its diverse clinical manifestations and the
inadequacy of conventional bacterial identiﬁcation methods. The
bacteriumis intrinsically resistant toawide rangeof antimicrobials,
and treatment with ineffective antimicrobials may result in case
fatality rates exceeding 70%. The global distribution of B. pseudoma-
llei and burden ofmelioidosis, however, remain poorly understood.
A globally comprehensive database was compiled, comprising
of 22,338 geo-located records of human and animal melioidosis
and presence of environmental B. pseudomallei from reports pub-
lished from 1910 to 2014. We then combined the data in a formal
modelling framework to predict the global distribution of B. pseu-
domallei and estimate the burden of melioidosis.
We estimate there to be 165,000 (95% credible interval 68,000-
412,000) human melioidosis cases per year worldwide, of which
89,000 (36,000-227,000) die. We predict that only 40% of all
melioidosis cases occur in the East Asia and Paciﬁc region, where
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melioidosis is considered highly endemic. By contrast, South Asia is
predicted to bear 44% of the overall burden, because large popula-
tions live in areas contaminatedwithB. pseudomallei. Our estimates
suggest that melioidosis is severely underreported in the 45 coun-
tries in which it is known to be endemic and that melioidosis is
likely endemic in a further 34 countries which have never reported
the disease.
The large numbers of estimated cases and fatalities emphasise
that the disease warrants renewed attention from public health
ofﬁcials and policy makers.
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Abstract: Largely due to its recognition as a biological
threat agent, current knowledge on melioidosis, caused by the
Gram-negative bacterium Burkholderia pseudomallei, has increased
tremendously in the last decade. In this talk, recent insights will be
given on our understanding on the molecular characterization of B.
pseudomallei and the immunology of melioidosis.
The genome of B. pseudomallei is composed of two chromo-
somes of which the largest part represents the B. pseudomallei
core genome, whereas the remaining accessory genome has been
associatedwith bacterial virulence. Virulence factors, most notably
quorum sensing, type III secretion system, lipopolysaccharide and
other surface polysaccharides, ﬂagella and various factors essential
for the intracellular life cycle of B. pseudomallei, have been further
characterized. These so calledmicroorganism associatedmolecular
patterns (MAMPs) are recognized by pattern recognition receptors
(PRRs) such as Toll-like receptors and NOD-like receptors (NLRs).
The neutrophils play a critical in host defense, which is initiated
by the TLRs. The proinﬂammatory immune response – including
the activation of coagulation – is further ignited by the release of
various damage associated molecular patterns (DAMPs) such as
calprotectin and the nucleosomes which are also recognized by
PRRs.
Severe melioidosis can probably be seen as the clinical manifes-
tation of a PRR mediated dysregulation of the immune response to
invading B. pseudomallei. B. pseudomallei employs numerous tactics
to evade the immune response. Studies on host–pathogen interac-
tions in melioidosis have identiﬁed a whole range of potential new
treatment targets which will be discussed.
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Abstract: For many years it has been clear that melioidosis is
endemic in parts of SE Asia and northern Australia, but over the
past 25 years, the melioidosis iceberg has been emerging. Within
known endemic areas, cases are being recognized with increasing
frequency. New endemic areas are also being identiﬁed, partic-
ularly in Africa and the Americas, but also in Asia. In Laos, for
example, the ﬁrst case of melioidosis was diagnosed as recently
as 1999, but since then more than 900 cases of culture-positive
melioidosis have been diagnosed in a single laboratory, although
this is just the tip of a national iceberg.
Worldwide, the disease undoubtedly remains under-diagnosed,
especially in the Indian sub-continent. The two main barriers to
the diagnosis of the disease, which has its biggest impact on the
rural poor, are access to high quality diagnostics, and the lack of
awareness and familiarity of clinical and laboratory staff. Clini-
cal diagnosis is difﬁcult due to the protean manifestations of the
disease. Where microbiology laboratories exist, the mainstay of
diagnosis remains culture. The organism is easy to grow as long
as the site of infection can be sampled, but laboratory technicians
unfamiliar with the organism may discard it as a contaminant.
An important clue is resistance to aminoglycosides and colistin
combined with susceptibility to co-amoxiclav, although regional
variantshave recentlybeendescribed. Latexagglutinationor lateral
ﬂow tests are useful for screening suspect isolates, and the latter
may be used for rapid diagnosis directly on clinical samples.Molec-
ular tests such as PCR have not yet found a role in routine diagnosis.
Available serological tests also lack sensitivity and speciﬁcity.
Current treatment regimens, comprising an initial parenteral
phase with either ceftazidime or a carbapenem followed by a pro-
longedoral eradicationphasewithco-trimoxazoleor co-amoxiclav,
are based on strong evidence from a series of clinical trials
conducted in Thailand. Several questions remain unanswered,
however, such as the optimal duration of each phase and the role
of adjunctive treatment.
Even with optimal antibiotic therapy the mortality in develop-
ing countries remains disappointingly high.
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